Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA4 | P22748 | 6/20 | 0.52 |
| ▸ | CA6 | P23280 | 4/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.31 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435657 | 1.00 | CA1 (0.52) | CA1CA2CA4CA6SLC18A3 | |
| SCHEMBL11993679 | 1.00 | CA1 (0.52) | CA1CA2CA4CA6SLC18A3 | |
| SCHEMBL12705972 | 1.00 | CA1 (0.52) | CA1CA2CA4CA6SLC18A3 | |
| SCHEMBL13602709 | 0.98 | CA1 (0.50) | CA1CA2CA4CA6SLC18A3 | |
| SCHEMBL13602711 | 0.98 | CA1 (0.50) | CA1CA2CA4CA6SLC18A3 | |
| SCHEMBL14984169 | 0.78 | CA1 (0.33) | CA1CA2CA4THRATHRB | |
| SCHEMBL13869192 | 0.77 | CA1 (0.44) | CA1CA2CA4 | |
| SCHEMBL9950816 | 0.73 | CA1 (0.35) | CA1CA2CA4 | |
| SCHEMBL20763610 | 0.73 | THRB (0.43) | THRB | |
| SCHEMBL20763857 | 0.73 | THRB (0.43) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| US-7919504-B2 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-09 | — | — | US | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298836-A1 | Thiadiazole modulators of PKB | PDK1, PDK2, MTOR | CA1 4779/4885CA2 3133/4885CA4 4573/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | CA1 1920/4885CA2 2512/4885CA4 2082/4885 |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | HSP90AA1, HSP90AB1, HSP90B1 | CA1 4137/4885CA2 4322/4885CA4 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.